77 related articles for article (PubMed ID: 2316546)
21. [Experiences with influence of the characteristics of drugs and type of excipient on drug release from suppositories].
Dalla Fini G; Dal Zotto M; Ragazzi E; Ragazzi E
Boll Chim Farm; 1986 Aug; 125(8):280-94. PubMed ID: 3814362
[No Abstract] [Full Text] [Related]
22. [Pharmaceutical problems of suppositories, IV: Hardening of suppositories as a result of chemical changes of the hard fat base?].
Thoma K; Precht D; Serno P
Arch Pharm (Weinheim); 1982 Aug; 315(8):729-32. PubMed ID: 7125868
[No Abstract] [Full Text] [Related]
23. Effects of surfactant characteristics on drug availability from suppositories.
Realdon N; Dal Zotto M; Morpurgo M; Franceschinis E
Pharmazie; 2008 Jun; 63(6):459-63. PubMed ID: 18604990
[TBL] [Abstract][Full Text] [Related]
24. [Correction of the fusion point of suppositories with semi-synthetic excipients].
Van Bosch F; Delrez M; De Nève R
Pharm Acta Helv; 1976; 51(4):106-12. PubMed ID: 967902
[No Abstract] [Full Text] [Related]
25. [Clinical experiences in the treatment of prostatic hypertrophy with high doses of progesterone administered rectally].
Marini A; Cavalca GG
Minerva Urol; 1974; 26(3):140-5. PubMed ID: 4138638
[No Abstract] [Full Text] [Related]
26. [Vaginal effervescent suppositories with a fatty base].
Neri G
Boll Chim Farm; 1967 Nov; 106(11):783-6. PubMed ID: 5629419
[No Abstract] [Full Text] [Related]
27. Efficacy of oral micronized progesterone when applied via vaginal route.
Choavaratana R; Manoch D
J Med Assoc Thai; 2004 May; 87(5):455-8. PubMed ID: 15222511
[TBL] [Abstract][Full Text] [Related]
28. Luteal phase deficiency and infertility: difficulties encountered in diagnosis and treatment.
Annos T; Thompson IE; Taymor ML
Obstet Gynecol; 1980 Jun; 55(6):705-10. PubMed ID: 7383457
[TBL] [Abstract][Full Text] [Related]
29. [The antioxidant action of 4,4'-(2,3-dimethyltetramethylene)-dipyrocatechol on essential oils of Njaouli and eucalyptus in suppositories prepared with fatty excipients].
FUMANERI AE; ORVIATI G
Boll Chim Farm; 1958 Jun; 97(6):346-9. PubMed ID: 13560633
[No Abstract] [Full Text] [Related]
30. [Fatty bases for the preparation of pediatric suppositories with spasmolytic activity].
Tentsova AI; Azhgikhin IS; Buzovs'kiĭ AN
Farm Zh; 1970; 25(6):49-54. PubMed ID: 5526476
[No Abstract] [Full Text] [Related]
31. [Semi-synthetic glycerides. Excipients for suppositories].
Ceschel G; Desantis A
Boll Chim Farm; 1969 Sep; 108(9):524-6. PubMed ID: 5364380
[No Abstract] [Full Text] [Related]
32. A randomized comparison of side effects and patient convenience between Cyclogest suppositories and Endometrin tablets used for luteal phase support in IVF treatment.
Ng EH; Chan CC; Tang OS; Ho PC
Eur J Obstet Gynecol Reprod Biol; 2007 Apr; 131(2):182-8. PubMed ID: 16920249
[TBL] [Abstract][Full Text] [Related]
33. The physiologic effectiveness of progesterone vaginal suppositories.
GREENBLATT RB
J Clin Endocrinol Metab; 1954 Dec; 14(12):1564-7. PubMed ID: 13211792
[No Abstract] [Full Text] [Related]
34. Development and evaluation of matrix and two layered sustained release suppositories of theophylline.
Maity S; Sa B; Bandyopadhyay AK
Boll Chim Farm; 2001; 140(6):462-6. PubMed ID: 11822240
[TBL] [Abstract][Full Text] [Related]
35. [The bioavailability of trapidil from suppositories (author's transl)].
Bornschein M; Grohmann A; Hackenberger F; Grune D
Pharmazie; 1981 Dec; 36(12):830-2. PubMed ID: 7330086
[TBL] [Abstract][Full Text] [Related]
36. [Coloration of fatty suppositories with carotinoid-dyes].
Münzel K; Füller W
Pharm Acta Helv; 1969 Apr; 44(4):208-37. PubMed ID: 5771377
[No Abstract] [Full Text] [Related]
37. Progesterone for premenstrual tension.
Norris RV
J Reprod Med; 1983 Aug; 28(8):509-16. PubMed ID: 6355465
[TBL] [Abstract][Full Text] [Related]
38. Compatibility of chewing gum excipients with the amino acid L-cysteine and stability of the active substance in directly compressed chewing gum formulation.
Kartal A; Björkqvist M; Lehto VP; Juppo AM; Marvola M; Sivén M
J Pharm Pharmacol; 2008 Sep; 60(9):1131-8. PubMed ID: 18718115
[TBL] [Abstract][Full Text] [Related]
39. Ovulation-inducing drugs versus progesterone therapy for infertility in patients with luteal phase defects.
Check JH; Nowroozi K; Wu CH; Adelson HG; Lauer C
Int J Fertil; 1988; 33(4):252-6. PubMed ID: 2902039
[TBL] [Abstract][Full Text] [Related]
40. [The influence of thermal constraints on the liberation of the active principal from the suppository form: the case of acetylsalicylic acid].
Lasserre Y; Peneva B; Jacob M; Puech A
J Pharm Belg; 1986; 41(1):12-6. PubMed ID: 3701563
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
